Bio Immunitas

+44 (0)20 7692 8489 info@bioimmunitas.com

INVESTORS & MEDIA

Bio Immunitas Ltd is led by an experienced team whose past achievements include

Awarded 2 USFDA Orphan Drug designations

Completed 2 separate UK MHRA registered Phase II double blind clinical trials successfully

> 0
years combined experience in biopharmaceuticals

selected publications by Professor Haq

> 0
years combined clinical experience

The longevity and anti-senescence market is expected to reach $44.2 billion by 2030*

* Opportunities and Forecast 2020-2030

Investor Opportunities

Phase 1

Phase 2

Phase 3

Pre-clinical GLP + GMP qualification + Phase I Safety clinical trial as a launchpad for multiple indications.

Two x Phase II double-blind controlled clinical trials.

Product launch and full market authorisation by the FDA and EMEA.

Bio Immunitas Ltd is an EIS-qualified Knowledge Intensive pharmaceutical company. All UK taxpayer investors, whether in the UK or overseas, can qualify for a minimum 30% tax rebate.

Funding already initiated for Phase 1 completion, with a view to Phase 2 clinical trial funding for specific indications, as defined in the pipeline.

Please get in touch for further information.

IP Position
in 2023

4 patents submitted in North America:
active patent filing program on-going with Fish & Richardson PC, Boston MA USA.